Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689741 | 0.86 | PHGDH (0.40) | MAPK14SLC5A1 | |
| SCHEMBL17778330 | 0.86 | PHGDH (0.40) | MAPK14SLC5A1 | |
| SCHEMBL19706590 | 0.85 | KDM4E (0.37) | MAPK14CA2CA9RPS6KA3SLC5A1 | |
| SCHEMBL19689827 | 0.84 | RAF1 (0.35) | MAPK13MAPK12MAPK11MAPK14CA2 | |
| SCHEMBL19689839 | 0.84 | RAF1 (0.35) | MAPK13MAPK12MAPK11MAPK14CA2 | |
| SCHEMBL17778231 | 0.84 | RAF1 (0.35) | MAPK13MAPK12MAPK11MAPK14CA2 | |
| SCHEMBL17778491 | 0.84 | RAF1 (0.35) | MAPK13MAPK12MAPK11MAPK14CA2 | |
| SCHEMBL19689840 | 0.84 | RAF1 (0.35) | MAPK13MAPK12MAPK11MAPK14CA2 | |
| SCHEMBL17768188 | 0.83 | ALDH1A1 (0.39) | — | |
| SCHEMBL17778549 | 0.82 | KDM4E (0.41) | MAPK14SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAPK13 1901/4885MAPK12 1769/4885MAPK11 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.